175:@0.890196:0.957873:0.914602:0.957873:0.914602:0.938882:0.890196:0.938882:0.007222:0.008593:0.008591
7:@0.941813:0.559752:0.963291:0.559752:0.963291:0.512274:0.941813:0.512274:0.021478
GENERAL DISCUSSION:@0.752908:0.064721:0.882355:0.064721:0.882355:0.047603:0.752908:0.047603:0.008404:0.006985:0.008759:0.006985:0.008423:0.007919:0.006294:0.002988:0.008423:0.003511:0.007807:0.008255:0.008367:0.007807:0.007807:0.003511:0.008442:0.008759
that the established PDOs are representative of the original tumor, with shallow genetic :@0.147059:0.121273:0.886443:0.121273:0.886443:0.100900:0.147059:0.100900:0.006620:0.011391:0.008811:0.006437:0.004657:0.006620:0.011299:0.009039:0.004657:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007553:0.011302:0.009106:0.011391:0.004657:0.011664:0.016504:0.016253:0.007670:0.004657:0.009085:0.007442:0.009039:0.004657:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006551:0.008811:0.006437:0.005547:0.009633:0.009039:0.004657:0.010845:0.006209:0.004657:0.006620:0.011299:0.009039:0.004657:0.010843:0.007807:0.005615:0.009861:0.005615:0.011687:0.009405:0.005250:0.004657:0.006163:0.011413:0.017488:0.010843:0.006255:0.004497:0.004657:0.014723:0.005273:0.006620:0.011459:0.004657:0.007556:0.011391:0.009405:0.005387:0.005182:0.010866:0.014723:0.004657:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.004109
characterizations using targeted gene panels or whole-exome sequencing. We, however, :@0.147059:0.141852:0.886441:0.141852:0.886441:0.121479:0.147059:0.121479:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004702:0.011413:0.007601:0.005615:0.011459:0.009861:0.004702:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004702:0.009656:0.009039:0.011596:0.009039:0.004702:0.011368:0.009085:0.011596:0.008948:0.005250:0.007670:0.004702:0.010843:0.007807:0.004702:0.014792:0.011299:0.010934:0.005182:0.009039:0.007533:0.009108:0.009884:0.010843:0.017485:0.009039:0.004702:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009679:0.004497:0.004702:0.018649:0.008743:0.004497:0.004702:0.011299:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.004109
provide a more comprehensive characterization with the use of whole genome sequenc-:@0.147059:0.162431:0.882353:0.162431:0.882353:0.142058:0.147059:0.142058:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009039:0.004154:0.009291:0.004154:0.017485:0.010843:0.007444:0.009039:0.004154:0.008994:0.010843:0.017280:0.011071:0.007442:0.008948:0.011299:0.009039:0.011619:0.007601:0.005547:0.009633:0.009039:0.004154:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.008811:0.006437:0.005547:0.010843:0.011756:0.004154:0.014723:0.005271:0.006620:0.011459:0.004154:0.006620:0.011299:0.009039:0.004154:0.011413:0.007875:0.009039:0.004154:0.010843:0.006209:0.004154:0.014792:0.011299:0.010934:0.005182:0.009039:0.004154:0.009656:0.009039:0.011598:0.010843:0.017485:0.009039:0.004154:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.009058:0.007533
ing (WGS) for genomic, RNA-seq for transcriptomic and even methylation arrays for :@0.147059:0.183009:0.886398:0.183009:0.886398:0.162636:0.147059:0.162636:0.005615:0.011459:0.009861:0.006140:0.006825:0.020270:0.015682:0.010112:0.006939:0.006140:0.006026:0.010843:0.007807:0.006140:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004497:0.006140:0.013376:0.015410:0.013602:0.007533:0.007875:0.009108:0.011025:0.006140:0.006026:0.010843:0.007807:0.006140:0.006437:0.007898:0.009085:0.011619:0.007875:0.008994:0.007807:0.005273:0.011048:0.006209:0.010843:0.017645:0.005547:0.008994:0.006140:0.009085:0.011596:0.011391:0.006140:0.009336:0.009635:0.009039:0.011756:0.006140:0.017485:0.009131:0.006620:0.011071:0.009793:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.006140:0.009085:0.007807:0.007898:0.008925:0.009724:0.007670:0.006140:0.006026:0.010843:0.007807:0.004109
epigenomic characterization, showing that the PDOs are representative of the corre-:@0.147059:0.203588:0.882353:0.203588:0.882353:0.183215:0.147059:0.183215:0.009131:0.011071:0.005615:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.007190:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.007190:0.007556:0.011299:0.010866:0.014723:0.005615:0.011459:0.009861:0.007190:0.006620:0.011391:0.008811:0.006437:0.007190:0.006620:0.011299:0.009039:0.007190:0.011664:0.016504:0.016253:0.007670:0.007190:0.009087:0.007442:0.009039:0.007190:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006551:0.008809:0.006437:0.005547:0.009635:0.009039:0.007190:0.010840:0.006209:0.007190:0.006620:0.011302:0.009039:0.007190:0.008994:0.010843:0.007807:0.007442:0.008989:0.007533
sponding tumor and that the heterogeneity that characterizes OC is captured in the bio-:@0.147059:0.224167:0.882353:0.224167:0.882353:0.203794:0.147059:0.203794:0.007510:0.011505:0.010843:0.011596:0.011391:0.005615:0.011459:0.009861:0.004086:0.006163:0.011413:0.017485:0.010843:0.007807:0.004086:0.009085:0.011596:0.011391:0.004086:0.006620:0.011391:0.008811:0.006437:0.004086:0.006620:0.011299:0.009039:0.004086:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.004086:0.006620:0.011391:0.008811:0.006437:0.004086:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.009039:0.007670:0.004086:0.016778:0.014678:0.004086:0.005615:0.007670:0.004086:0.009108:0.008811:0.011048:0.006163:0.011413:0.007442:0.009108:0.011391:0.004086:0.005615:0.011756:0.004086:0.006620:0.011299:0.009039:0.004086:0.010820:0.005547:0.011000:0.007533
bank. Moreover, by characterizing PDOs after long term passaging we show that those :@0.147059:0.244745:0.886423:0.244745:0.886423:0.224373:0.147059:0.224373:0.011117:0.009085:0.011870:0.010523:0.004497:0.005296:0.018969:0.010843:0.007444:0.009106:0.010866:0.009633:0.009039:0.006255:0.004497:0.005296:0.010843:0.009724:0.005296:0.008768:0.011391:0.009085:0.007898:0.009291:0.009106:0.006211:0.009039:0.007807:0.005615:0.008834:0.005615:0.011459:0.009861:0.005296:0.011664:0.016504:0.016253:0.007670:0.005296:0.009085:0.006197:0.005971:0.009039:0.007807:0.005296:0.005182:0.010843:0.011459:0.009861:0.005296:0.006209:0.009039:0.007807:0.017645:0.005296:0.011368:0.009291:0.007533:0.007944:0.009199:0.009861:0.005615:0.011459:0.009861:0.005296:0.014518:0.009039:0.005296:0.007556:0.011302:0.010863:0.014723:0.005296:0.006620:0.011391:0.008811:0.006437:0.005296:0.006620:0.011299:0.010957:0.007875:0.009039:0.004109
features are maintained well over time. We also show examples of potential applications :@0.147059:0.265324:0.886459:0.265324:0.886459:0.244951:0.147059:0.244951:0.006026:0.009291:0.008811:0.006163:0.011413:0.007442:0.009039:0.007670:0.004463:0.009085:0.007442:0.009039:0.004463:0.017577:0.009085:0.005615:0.011391:0.006551:0.009085:0.005615:0.011596:0.009108:0.011391:0.004463:0.014518:0.008948:0.005387:0.005250:0.004460:0.010868:0.009633:0.009039:0.007807:0.004463:0.006437:0.005615:0.017485:0.008743:0.004497:0.004460:0.018649:0.009039:0.004463:0.009405:0.005250:0.007875:0.011048:0.004463:0.007556:0.011299:0.010866:0.014723:0.004463:0.009108:0.010089:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004463:0.010843:0.006209:0.004463:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009402:0.005250:0.004463:0.008811:0.011048:0.011162:0.005250:0.005547:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004109
of the biobank by using genome editing techniques to model the origin of OC and also :@0.147059:0.285903:0.886414:0.285903:0.886414:0.265530:0.147059:0.265530:0.010843:0.006209:0.004816:0.006620:0.011299:0.009039:0.004816:0.010820:0.005547:0.010957:0.011114:0.009087:0.011868:0.010523:0.004816:0.010843:0.009724:0.004816:0.011413:0.007601:0.005615:0.011459:0.009861:0.004816:0.009656:0.009039:0.011596:0.010843:0.017485:0.009039:0.004816:0.009106:0.011391:0.005273:0.006437:0.005615:0.011459:0.009861:0.004816:0.006211:0.009106:0.008768:0.011459:0.011756:0.005545:0.010706:0.011345:0.009039:0.007670:0.004816:0.006209:0.011048:0.004816:0.017485:0.011276:0.011322:0.008948:0.005250:0.004816:0.006620:0.011299:0.009039:0.004816:0.010843:0.007807:0.005615:0.009861:0.005615:0.011756:0.004816:0.010843:0.006209:0.004816:0.016778:0.014678:0.004816:0.009085:0.011596:0.011391:0.004816:0.009405:0.005250:0.007875:0.011048:0.004109
performing drug screening with drugs that are commonly used in OC treatment, even :@0.147059:0.306482:0.886573:0.306482:0.886573:0.286109:0.147059:0.286109:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017645:0.005615:0.011459:0.009861:0.005227:0.011391:0.007964:0.011413:0.009861:0.005227:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.005227:0.014723:0.005273:0.006620:0.011459:0.005227:0.011391:0.007964:0.011413:0.009724:0.007670:0.005227:0.006620:0.011391:0.008811:0.006437:0.005227:0.009085:0.007442:0.009039:0.005227:0.008994:0.010843:0.017645:0.017485:0.010843:0.011870:0.005182:0.009724:0.005227:0.011413:0.007875:0.009108:0.011391:0.005227:0.005615:0.011756:0.005227:0.016778:0.014678:0.005227:0.006437:0.007442:0.009288:0.008811:0.006437:0.017488:0.009039:0.011391:0.006437:0.004497:0.005227:0.009336:0.009633:0.009039:0.011756:0.004109
assessing their response :@0.147059:0.327060:0.350443:0.327060:0.350443:0.306687:0.147059:0.306687:0.009291:0.007533:0.007875:0.009039:0.007533:0.007601:0.005615:0.011459:0.009861:0.004109:0.006620:0.011299:0.009039:0.005615:0.007807:0.004109:0.007442:0.009039:0.007510:0.011502:0.010843:0.011619:0.007875:0.009039:0.004109
in vivo:@0.350444:0.327060:0.404543:0.327060:0.404543:0.306477:0.350444:0.306477:0.005090:0.011299:0.004200:0.009291:0.005159:0.009131:0.009930
 after xenotransplantation into mice. :@0.404543:0.327060:0.713777:0.327060:0.713777:0.306687:0.404543:0.306687:0.004109:0.009085:0.006197:0.005969:0.009039:0.007807:0.004109:0.009884:0.009039:0.011596:0.010820:0.006437:0.007898:0.009085:0.011619:0.007510:0.011162:0.005433:0.009085:0.011391:0.006551:0.008811:0.006437:0.005547:0.010843:0.011756:0.004109:0.005615:0.011391:0.006209:0.011048:0.004109:0.017645:0.005547:0.008994:0.008743:0.004497:0.004109
Another strength of our biobank is the establishment of PDO lines from different tu-:@0.147059:0.368218:0.882353:0.368218:0.882353:0.347845:0.147059:0.347845:0.014929:0.011596:0.010820:0.006620:0.011299:0.009039:0.007807:0.006026:0.007510:0.006437:0.007442:0.009039:0.011459:0.009861:0.006620:0.011459:0.006026:0.010843:0.006209:0.006026:0.010820:0.011413:0.007807:0.006026:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.006026:0.005615:0.007670:0.006026:0.006620:0.011299:0.009039:0.006026:0.009039:0.007512:0.006549:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.017485:0.009039:0.011391:0.006437:0.006026:0.010843:0.006209:0.006026:0.011664:0.016504:0.016412:0.006026:0.005250:0.005615:0.011598:0.009039:0.007670:0.006026:0.006414:0.007442:0.010843:0.017645:0.006026:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.006026:0.006163:0.011454:0.007533
mor locations of the same patient. While in :@0.147059:0.388796:0.513794:0.388796:0.513794:0.368423:0.147059:0.368423:0.017485:0.010843:0.007807:0.004200:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004200:0.010843:0.006209:0.004200:0.006620:0.011299:0.009039:0.004200:0.007944:0.009085:0.017485:0.009039:0.004200:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004497:0.004200:0.020704:0.011459:0.005752:0.005182:0.009039:0.004200:0.005615:0.011756:0.004109
chapter 2:@0.513951:0.388796:0.595831:0.388796:0.595831:0.367664:0.513951:0.367664:0.009085:0.011779:0.009542:0.011733:0.006871:0.009268:0.008583:0.004109:0.010911
 we describe how the intra-patient :@0.595837:0.388796:0.886419:0.388796:0.886419:0.368423:0.595837:0.368423:0.004200:0.014518:0.009039:0.004200:0.011322:0.009039:0.007875:0.008994:0.007807:0.005547:0.011254:0.009039:0.004200:0.011299:0.010866:0.014723:0.004200:0.006620:0.011299:0.009039:0.004200:0.005615:0.011391:0.006437:0.007898:0.009291:0.007533:0.011365:0.008813:0.006437:0.005545:0.009039:0.011391:0.006437:0.004109
genomic heterogeneity is preserved, in :@0.147059:0.409375:0.476929:0.409375:0.476929:0.389002:0.147059:0.389002:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004908:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.004908:0.005615:0.007670:0.004908:0.011073:0.007442:0.009039:0.007873:0.009039:0.008400:0.009633:0.009108:0.011117:0.004497:0.004908:0.005615:0.011756:0.004109
chapter 3:@0.477759:0.409375:0.560335:0.409375:0.560335:0.388242:0.477759:0.388242:0.009085:0.011779:0.009542:0.011733:0.006871:0.009268:0.008583:0.004805:0.010911
 we expand to study how these related :@0.560335:0.409375:0.886416:0.409375:0.886416:0.389002:0.560335:0.389002:0.004908:0.014518:0.009039:0.004908:0.009108:0.010089:0.011365:0.009085:0.011596:0.011391:0.004908:0.006209:0.011048:0.004908:0.007510:0.006166:0.011345:0.011322:0.009724:0.004908:0.011302:0.010863:0.014723:0.004908:0.006620:0.011299:0.009039:0.007875:0.009039:0.004908:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.004109
locations can respond differently to the same drug. There, we found differential respons-:@0.147059:0.429954:0.882353:0.429954:0.882353:0.409581:0.147059:0.409581:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.003881:0.009108:0.009085:0.011756:0.003881:0.007442:0.009039:0.007512:0.011502:0.010843:0.011596:0.011391:0.003881:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006620:0.005182:0.009724:0.003881:0.006209:0.011048:0.003881:0.006622:0.011299:0.009039:0.003881:0.007944:0.009085:0.017488:0.009039:0.003881:0.011391:0.007967:0.011413:0.009679:0.004497:0.003881:0.011470:0.011311:0.009039:0.007442:0.008743:0.004497:0.003881:0.014518:0.009039:0.003881:0.006026:0.010820:0.011413:0.011596:0.011391:0.003881:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.003881:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007686:0.007533
es to at least one drug in each of these patients. This suggests that tumor heterogeneity :@0.147059:0.450532:0.886464:0.450532:0.886464:0.430160:0.147059:0.430160:0.009039:0.007670:0.005376:0.006209:0.011048:0.005373:0.008811:0.006437:0.005376:0.005182:0.009291:0.009291:0.007510:0.006437:0.005376:0.010843:0.011596:0.009039:0.005373:0.011391:0.007967:0.011413:0.009861:0.005376:0.005615:0.011756:0.005373:0.009291:0.009291:0.008765:0.011459:0.005376:0.010843:0.006209:0.005373:0.006620:0.011302:0.009039:0.007873:0.009039:0.005376:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.005373:0.011470:0.011470:0.005615:0.007670:0.005376:0.007510:0.011413:0.009975:0.009656:0.009039:0.007510:0.006437:0.007670:0.005373:0.006620:0.011393:0.008811:0.006437:0.005376:0.006163:0.011413:0.017485:0.010843:0.007807:0.005376:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.004109
can also involve multiple locations of the same patient, influencing treatment efficacy :@0.147059:0.471111:0.886462:0.471111:0.886462:0.450738:0.147059:0.450738:0.009108:0.009085:0.011756:0.006309:0.009405:0.005250:0.007875:0.011048:0.006312:0.005615:0.011368:0.009633:0.010934:0.005182:0.009633:0.009039:0.006309:0.017280:0.011550:0.004910:0.006437:0.005271:0.011162:0.005182:0.009039:0.006312:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.006309:0.010843:0.006209:0.006312:0.006620:0.011299:0.009039:0.006309:0.007944:0.009085:0.017485:0.009039:0.006312:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004497:0.006309:0.005615:0.011756:0.005638:0.005296:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.006312:0.006437:0.007442:0.009291:0.008809:0.006437:0.017488:0.009039:0.011391:0.006437:0.006309:0.009039:0.005692:0.005692:0.005623:0.009108:0.009291:0.009382:0.009724:0.004109
and resistance development. Establishing organoids from all the tumor locations from :@0.147059:0.491690:0.886375:0.491690:0.886375:0.471317:0.147059:0.471317:0.009085:0.011596:0.011391:0.005615:0.007442:0.009039:0.007601:0.005615:0.007510:0.006551:0.009085:0.011596:0.008994:0.009039:0.005615:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011071:0.017485:0.009039:0.011391:0.006437:0.004497:0.005615:0.012098:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.005615:0.011459:0.009861:0.005615:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.005615:0.006414:0.007442:0.010843:0.017645:0.005615:0.009405:0.005387:0.005250:0.005615:0.006620:0.011299:0.009039:0.005615:0.006163:0.011413:0.017485:0.010843:0.007807:0.005615:0.005182:0.011276:0.009108:0.008811:0.006437:0.005549:0.010843:0.011619:0.007670:0.005615:0.006412:0.007442:0.010845:0.017645:0.004109
a patient can enable the screening of multiple drugs and the selection of different effec-:@0.147059:0.512269:0.882353:0.512269:0.882353:0.491896:0.147059:0.491896:0.009291:0.004885:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004885:0.009108:0.009085:0.011756:0.004885:0.009039:0.011687:0.009108:0.010911:0.005182:0.009039:0.004885:0.006620:0.011299:0.009039:0.004885:0.007873:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.004885:0.010843:0.006209:0.004885:0.017280:0.011550:0.004908:0.006437:0.005273:0.011162:0.005182:0.009039:0.004885:0.011391:0.007967:0.011413:0.009724:0.007670:0.004885:0.009087:0.011596:0.011391:0.004885:0.006620:0.011302:0.009039:0.004885:0.007875:0.008948:0.005182:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.004885:0.010843:0.006209:0.004885:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.004885:0.009039:0.005969:0.005787:0.009106:0.009083:0.007533
tive treatments that work for all of them. In order to achieve this stage, fast PDO culture :@0.147059:0.532847:0.886603:0.532847:0.886603:0.512474:0.147059:0.512474:0.006437:0.005547:0.009633:0.009039:0.004383:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.007670:0.004383:0.006620:0.011391:0.008811:0.006437:0.004383:0.014518:0.010843:0.007601:0.010523:0.004383:0.006026:0.010843:0.007807:0.004383:0.009402:0.005387:0.005250:0.004383:0.010843:0.006209:0.004383:0.006620:0.011299:0.009039:0.017645:0.004497:0.004383:0.006894:0.011756:0.004383:0.010845:0.007442:0.011322:0.009039:0.007807:0.004383:0.006209:0.011048:0.004383:0.009291:0.008765:0.011459:0.005547:0.009336:0.009633:0.009039:0.004383:0.006620:0.011459:0.005615:0.007670:0.004383:0.007512:0.006549:0.009199:0.009656:0.008745:0.004497:0.004383:0.006209:0.009291:0.007510:0.006437:0.004383:0.011664:0.016504:0.016412:0.004383:0.009108:0.011550:0.004908:0.006163:0.011413:0.007442:0.009039:0.004109
establishment with high success rate to ensure that all locations from all patients can be :@0.147059:0.553426:0.886368:0.553426:0.886368:0.533053:0.147059:0.533053:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.017485:0.009039:0.011391:0.006437:0.004702:0.014723:0.005273:0.006620:0.011459:0.004702:0.011459:0.005615:0.009930:0.011459:0.004702:0.007510:0.011345:0.008994:0.008994:0.009039:0.007533:0.007670:0.004702:0.007898:0.008811:0.006209:0.009039:0.004702:0.006209:0.011048:0.004702:0.009039:0.011619:0.007510:0.011413:0.007442:0.009039:0.004702:0.006620:0.011391:0.008811:0.006437:0.004702:0.009402:0.005387:0.005250:0.004702:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004702:0.006414:0.007442:0.010843:0.017645:0.004702:0.009402:0.005387:0.005250:0.004702:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004702:0.009108:0.009085:0.011756:0.004702:0.011254:0.009039:0.004109
represented in a clinically relevant timeframe, as well as standardized drug assays and :@0.147059:0.574005:0.886368:0.574005:0.886368:0.553632:0.147059:0.553632:0.007442:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006209:0.009108:0.011391:0.006026:0.005615:0.011756:0.006026:0.009291:0.006026:0.008765:0.005250:0.005615:0.011756:0.005547:0.009106:0.009405:0.005387:0.005182:0.009724:0.006026:0.007442:0.008948:0.005182:0.009336:0.009838:0.009085:0.011391:0.006437:0.006026:0.006437:0.005615:0.017485:0.009039:0.006414:0.007898:0.009085:0.017485:0.008743:0.004497:0.006026:0.009291:0.007670:0.006026:0.014516:0.008950:0.005385:0.005250:0.006026:0.009291:0.007670:0.006026:0.007510:0.006551:0.009085:0.011596:0.011573:0.009085:0.007442:0.011391:0.005615:0.008834:0.009108:0.011391:0.006026:0.011391:0.007967:0.011413:0.009861:0.006026:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.006026:0.009085:0.011596:0.011391:0.004109
well-defined controls to evaluate organoid response are needed. :@0.147059:0.594583:0.683828:0.594583:0.683828:0.574210:0.147059:0.574210:0.014518:0.008948:0.005387:0.005250:0.007533:0.011322:0.009039:0.005684:0.005684:0.011596:0.009108:0.011391:0.004109:0.008994:0.010840:0.011391:0.006437:0.007444:0.010934:0.005250:0.007670:0.004109:0.006209:0.011048:0.004109:0.009334:0.009838:0.009405:0.004908:0.011596:0.008811:0.006209:0.009039:0.004109:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.004109:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004109:0.009085:0.007442:0.009039:0.004109:0.011596:0.009108:0.009108:0.011322:0.009106:0.011119:0.004497:0.004109
There are several possibilities to improve success rates when establishing organoid lines :@0.147059:0.635741:0.886478:0.635741:0.886478:0.615368:0.147059:0.615368:0.011470:0.011311:0.009039:0.007442:0.009039:0.004759:0.009085:0.007444:0.009039:0.004759:0.007875:0.009336:0.009633:0.009039:0.007898:0.009405:0.005250:0.004759:0.011505:0.010957:0.007533:0.007601:0.005547:0.010820:0.005752:0.005250:0.005271:0.006437:0.005547:0.009039:0.007670:0.004771:0.006209:0.011048:0.004759:0.005615:0.017280:0.011071:0.007442:0.010866:0.009633:0.009039:0.004759:0.007512:0.011345:0.008994:0.008994:0.009039:0.007533:0.007670:0.004759:0.007898:0.008811:0.006209:0.009039:0.007670:0.004759:0.014792:0.011299:0.009039:0.011756:0.004759:0.009039:0.007512:0.006549:0.009110:0.010909:0.005250:0.005615:0.007556:0.011459:0.005615:0.011459:0.009861:0.004771:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.004759:0.005250:0.005615:0.011596:0.009039:0.007670:0.004109
from patients with OC. Most of the tumors we sampled for organoid derivation had been :@0.147059:0.656319:0.886325:0.656319:0.886325:0.635947:0.147059:0.635947:0.006414:0.007442:0.010843:0.017645:0.003333:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.003333:0.014723:0.005273:0.006620:0.011459:0.003333:0.016778:0.014678:0.004497:0.003333:0.018969:0.010957:0.007510:0.006437:0.003333:0.010843:0.006209:0.003333:0.006617:0.011302:0.009039:0.003333:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.003333:0.014518:0.009039:0.003333:0.007941:0.009087:0.017280:0.011162:0.005182:0.009106:0.011391:0.003333:0.006026:0.010843:0.007807:0.003333:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.003333:0.011322:0.009039:0.007807:0.005547:0.009838:0.008811:0.006437:0.005547:0.010843:0.011756:0.003333:0.011393:0.009291:0.011391:0.003333:0.011251:0.009108:0.009039:0.011756:0.004109
previously exposed to chemotherapy, since the tissue samples were obtained during in-:@0.147059:0.676898:0.882353:0.676898:0.882353:0.656525:0.147059:0.656525:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.004862:0.009108:0.010089:0.011502:0.010957:0.007875:0.009108:0.011391:0.004862:0.006209:0.011048:0.004862:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.007989:0.004497:0.004862:0.007601:0.005615:0.011596:0.008994:0.009039:0.004862:0.006620:0.011299:0.009039:0.004862:0.006437:0.005615:0.007533:0.007510:0.011345:0.009039:0.004862:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004862:0.014518:0.009039:0.007442:0.009039:0.004862:0.010959:0.010795:0.006551:0.009085:0.005615:0.011596:0.009108:0.011391:0.004862:0.011048:0.011413:0.007807:0.005615:0.011459:0.009861:0.004862:0.005615:0.011801:0.007533
terval debulking as part of the standard treatment for OC. Therefore, the tumor viability :@0.147059:0.697477:0.886484:0.697477:0.886484:0.677104:0.147059:0.677104:0.006209:0.009039:0.008400:0.009838:0.009405:0.005250:0.004120:0.011322:0.008902:0.010797:0.011550:0.005387:0.010706:0.005615:0.011459:0.009861:0.004120:0.009291:0.007670:0.004120:0.011368:0.009085:0.007967:0.006437:0.004120:0.010843:0.006209:0.004132:0.006620:0.011299:0.009039:0.004120:0.007510:0.006551:0.009085:0.011596:0.011573:0.009085:0.007442:0.011391:0.004132:0.006437:0.007442:0.009288:0.008811:0.006437:0.017488:0.009039:0.011391:0.006437:0.004120:0.006026:0.010843:0.007807:0.004120:0.016778:0.014678:0.004497:0.004120:0.011470:0.011311:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.008743:0.004497:0.004132:0.006620:0.011299:0.009039:0.004120:0.006163:0.011413:0.017485:0.010843:0.007807:0.004120:0.009838:0.005796:0.009108:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.004109
might be already compromised prior to culture establishment due to the genomic dam-:@0.147059:0.718056:0.882353:0.718056:0.882353:0.697683:0.147059:0.697683:0.017645:0.005615:0.009930:0.011094:0.006437:0.004360:0.011251:0.009039:0.004360:0.009405:0.005250:0.007442:0.009291:0.009291:0.011322:0.009724:0.004360:0.008994:0.010843:0.017280:0.011071:0.007442:0.010843:0.017645:0.005615:0.007875:0.009108:0.011391:0.004360:0.011071:0.007807:0.005547:0.010843:0.007807:0.004360:0.006209:0.011048:0.004360:0.009108:0.011550:0.004908:0.006163:0.011413:0.007442:0.009039:0.004360:0.009039:0.007510:0.006551:0.009108:0.010909:0.005250:0.005615:0.007556:0.011459:0.017488:0.009039:0.011391:0.006437:0.004360:0.011048:0.011345:0.009039:0.004360:0.006209:0.011048:0.004360:0.006620:0.011299:0.009039:0.004360:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004360:0.011573:0.009085:0.017668:0.007533
age induced by the chemotherapeutic agents. To overcome this, obtaining biopsies prior :@0.147059:0.738634:0.886395:0.738634:0.886395:0.718261:0.147059:0.718261:0.009199:0.009656:0.009039:0.004086:0.005615:0.011596:0.011048:0.011345:0.008994:0.009108:0.011391:0.004086:0.010843:0.009724:0.004086:0.006620:0.011299:0.009039:0.004086:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011505:0.009131:0.011071:0.006437:0.005547:0.008994:0.004086:0.009199:0.009656:0.009039:0.011391:0.006437:0.007670:0.004497:0.004086:0.010866:0.011048:0.004086:0.010866:0.009633:0.009039:0.007442:0.008994:0.010843:0.017485:0.009039:0.004086:0.006620:0.011459:0.005615:0.007670:0.004497:0.004086:0.010957:0.010797:0.006551:0.009085:0.005615:0.011756:0.005615:0.011459:0.009861:0.004086:0.010820:0.005547:0.010820:0.011185:0.007601:0.005547:0.009039:0.007670:0.004086:0.011071:0.007807:0.005547:0.010843:0.007807:0.004109
to chemotherapy exposure or selection of areas with higher tumor purity and viability :@0.147059:0.759213:0.886482:0.759213:0.886482:0.738840:0.147059:0.738840:0.006209:0.011048:0.005593:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.009724:0.005593:0.009108:0.010089:0.011505:0.010957:0.007510:0.011413:0.007442:0.009039:0.005593:0.010843:0.007807:0.005593:0.007873:0.008948:0.005182:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.005593:0.010843:0.006209:0.005593:0.009085:0.007442:0.009291:0.009291:0.007670:0.005593:0.014723:0.005271:0.006620:0.011459:0.005593:0.011459:0.005615:0.009927:0.011299:0.009039:0.007807:0.005593:0.006166:0.011413:0.017485:0.010843:0.007807:0.005593:0.011048:0.011413:0.007807:0.005273:0.006437:0.009724:0.005593:0.009085:0.011596:0.011391:0.005593:0.009838:0.005798:0.009108:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.004109
prior to plating, would be ideal. Furthermore, different growth factors used in the medi-:@0.147059:0.779792:0.882353:0.779792:0.882353:0.759419:0.147059:0.759419:0.011071:0.007807:0.005547:0.010843:0.007807:0.004154:0.006209:0.011048:0.004154:0.011162:0.005433:0.008811:0.006437:0.005615:0.011459:0.009679:0.004497:0.004154:0.014518:0.010820:0.011550:0.005182:0.011391:0.004154:0.011251:0.009039:0.004154:0.005547:0.011322:0.009288:0.009405:0.004976:0.004497:0.004154:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.004154:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.004154:0.009861:0.007442:0.010866:0.014723:0.006620:0.011459:0.004154:0.006209:0.009291:0.009108:0.006209:0.010843:0.007624:0.007670:0.004154:0.011413:0.007875:0.009106:0.011391:0.004154:0.005615:0.011756:0.004154:0.006620:0.011299:0.009039:0.004154:0.017485:0.009108:0.011391:0.005529:0.007533
um might be driving selection for certain samples depending on their specific molecular :@0.147059:0.800370:0.886416:0.800370:0.886416:0.779998:0.147059:0.779998:0.011413:0.017645:0.003766:0.017645:0.005615:0.009927:0.011096:0.006437:0.003766:0.011254:0.009039:0.003766:0.011391:0.007807:0.005547:0.009838:0.005615:0.011459:0.009861:0.003766:0.007875:0.008948:0.005182:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.003766:0.006026:0.010843:0.007807:0.003766:0.008994:0.009039:0.007967:0.006551:0.009085:0.005615:0.011756:0.003766:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.003766:0.011322:0.009131:0.011502:0.009039:0.011598:0.011391:0.005615:0.011459:0.009861:0.003766:0.010843:0.011756:0.003766:0.006620:0.011299:0.009039:0.005615:0.007807:0.003766:0.007510:0.011502:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.003766:0.017485:0.010934:0.005182:0.009108:0.009108:0.011550:0.005433:0.009085:0.007807:0.004109
characteristics. For example, nicotinamide is a growth factor used in our organoid medi-:@0.147059:0.820949:0.882353:0.820949:0.882353:0.800576:0.147059:0.800576:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.007510:0.006437:0.005547:0.008994:0.007670:0.004497:0.003698:0.010683:0.010843:0.007807:0.003698:0.009108:0.010089:0.009085:0.017280:0.011160:0.005182:0.008745:0.004497:0.003698:0.011756:0.005547:0.008994:0.010820:0.006437:0.005615:0.011687:0.009085:0.017645:0.005547:0.011322:0.009039:0.003698:0.005615:0.007670:0.003698:0.009291:0.003698:0.009861:0.007442:0.010866:0.014723:0.006620:0.011459:0.003698:0.006209:0.009291:0.009108:0.006209:0.010843:0.007807:0.003698:0.011413:0.007875:0.009108:0.011391:0.003698:0.005615:0.011756:0.003698:0.010820:0.011413:0.007807:0.003698:0.010843:0.007624:0.009861:0.009085:0.011598:0.010843:0.005547:0.011391:0.003698:0.017485:0.009108:0.011391:0.005565:0.007533
um and also in previous organoid biobanks. However, nicotinamide is also a PARP-in-:@0.147059:0.841528:0.882353:0.841528:0.882353:0.821155:0.147059:0.821155:0.011413:0.017645:0.004976:0.009085:0.011596:0.011391:0.004976:0.009405:0.005250:0.007873:0.011048:0.004976:0.005615:0.011756:0.004976:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007670:0.004976:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.004976:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.007670:0.004497:0.004976:0.016207:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.004976:0.011756:0.005547:0.008994:0.010820:0.006437:0.005615:0.011687:0.009085:0.017645:0.005547:0.011322:0.009039:0.004976:0.005615:0.007670:0.004976:0.009405:0.005250:0.007873:0.011048:0.004976:0.009291:0.004976:0.010249:0.014929:0.013376:0.010592:0.007533:0.005615:0.011667:0.007533
hibitor, which is a compound that inhibits DNA repair by the homologous recombina-:@0.147059:0.862107:0.882353:0.862107:0.882353:0.841734:0.147059:0.841734:0.011459:0.005547:0.010820:0.005273:0.006209:0.010843:0.006255:0.004497:0.004908:0.014792:0.011459:0.005547:0.008765:0.011459:0.004908:0.005615:0.007670:0.004908:0.009291:0.004908:0.008994:0.010843:0.017280:0.011505:0.010820:0.011413:0.011596:0.011391:0.004908:0.006620:0.011391:0.008811:0.006437:0.004908:0.005615:0.011870:0.011459:0.005547:0.010820:0.005273:0.006437:0.007670:0.004908:0.015773:0.015408:0.014929:0.004908:0.007442:0.009131:0.011368:0.009085:0.005615:0.007807:0.004908:0.010840:0.009724:0.004908:0.006620:0.011299:0.009039:0.004908:0.011299:0.010843:0.017485:0.010934:0.005182:0.011048:0.009656:0.010820:0.011413:0.007670:0.004908:0.007442:0.009106:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.009247:0.007533
tion (HR) machinery. PARP-inhibitors are thus effective drugs for HR-deficient tumors, :@0.147059:0.882685:0.886505:0.882685:0.886505:0.862312:0.147059:0.862312:0.006437:0.005547:0.010843:0.011756:0.004246:0.006939:0.016846:0.013376:0.006939:0.004246:0.017577:0.009291:0.008765:0.011459:0.005615:0.011596:0.009039:0.008400:0.007989:0.004497:0.004246:0.010249:0.014929:0.013376:0.010592:0.007533:0.005615:0.011868:0.011459:0.005547:0.010820:0.005273:0.006209:0.010843:0.007624:0.007670:0.004246:0.009085:0.007442:0.009039:0.004246:0.006620:0.011094:0.011413:0.007670:0.004246:0.009039:0.005969:0.005787:0.009106:0.009108:0.006437:0.005547:0.009633:0.009039:0.004246:0.011391:0.007967:0.011413:0.009724:0.007670:0.004246:0.006026:0.010843:0.007807:0.004246:0.016846:0.012349:0.007533:0.011322:0.009039:0.005684:0.005615:0.008994:0.005547:0.009039:0.011391:0.006437:0.004246:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.004497:0.004109
such as those with BRCA1 or BRCA2 inactivation. Nevertheless, in this case, it might be :@0.147059:0.903264:0.886576:0.903264:0.886576:0.882891:0.147059:0.882891:0.007510:0.011345:0.008765:0.011459:0.004040:0.009291:0.007670:0.004040:0.006620:0.011299:0.010957:0.007875:0.009039:0.004040:0.014723:0.005273:0.006620:0.011459:0.004040:0.012463:0.013308:0.014678:0.014929:0.010432:0.004040:0.010843:0.007807:0.004040:0.012463:0.013308:0.014678:0.014929:0.010432:0.004040:0.005615:0.011687:0.009291:0.009108:0.006437:0.005547:0.009838:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.004040:0.015522:0.009336:0.009633:0.009039:0.007964:0.006620:0.011299:0.008948:0.005182:0.009039:0.007533:0.007670:0.004497:0.004040:0.005615:0.011756:0.004040:0.006620:0.011459:0.005615:0.007670:0.004040:0.009108:0.009291:0.007875:0.008743:0.004497:0.004040:0.005273:0.006437:0.004040:0.017645:0.005615:0.009930:0.011094:0.006437:0.004040:0.011254:0.009039:0.004109